tenofovir has been researched along with Dermatoses in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Corciulo, C; Cronstein, B; Feig, JL; Liu, H; Mediero, A; Perez-Aso, M; Picard, L; Wilder, T; Zhang, J | 1 |
| Brieva, J; Kosche, C; Nardone, B; Palella, FJ; Para, A; West, DP | 1 |
| Martin, L | 1 |
1 review(s) available for tenofovir and Dermatoses
| Article | Year |
|---|---|
[What's new in dermatological treatments?].
Topics: Adenine; Anti-HIV Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Clinical Trials as Topic; Cyclosporine; Dermatofibrosarcoma; Dermatologic Agents; Dermatology; Drug Therapy, Combination; Etanercept; Follow-Up Studies; Gels; HIV Infections; Humans; Imatinib Mesylate; Immunoglobulin G; Immunosuppressive Agents; Ipilimumab; Melanoma; Neoplasm Staging; Organophosphonates; Piperazines; Psoriasis; Pyrimidines; Receptors, Tumor Necrosis Factor; Skin Diseases; Skin Neoplasms; Survival Analysis; Tenofovir; Treatment Outcome; Ustekinumab | 2010 |
2 other study(ies) available for tenofovir and Dermatoses
| Article | Year |
|---|---|
The antiviral drug tenofovir, an inhibitor of Pannexin-1-mediated ATP release, prevents liver and skin fibrosis by downregulating adenosine levels in the liver and skin.
Topics: Adenosine; Adenosine Triphosphate; Animals; Antiviral Agents; Connexins; Disease Models, Animal; Dose-Response Relationship, Drug; Liver; Liver Cirrhosis; Male; Mice; Mice, Inbred C57BL; Nerve Tissue Proteins; Skin; Skin Diseases; Tenofovir | 2017 |
Incidence of cutaneous adverse events after exposure to tenofovir-emtricitabine in HIV-uninfected vs HIV-infected patients: pharmacovigilance within a large Midwestern U.S. patient population from the Research on Adverse Drug events And Reports program.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Drug Therapy, Combination; Emtricitabine; Female; HIV Infections; Humans; Incidence; Male; Middle Aged; Midwestern United States; Pharmacovigilance; Skin Diseases; Tenofovir; Young Adult | 2019 |